April 15, 2013 — Tomosynthesis (3-D mammography) is better able to show infiltrating ductal carcinoma than 2-D mammography in women at increased risk of breast cancer, a new clinical study shows.

As part of the study, six breast imaging specialists reviewed both 2-D and 3-D mammography images of 56 cancers diagnosed in patients at intermediate or high risk of breast cancer.

"We found that 41 percent (23/56 cancers) were better seen on tomosynthesis and 4 percent (2/56) were only seen on tomosynthesis," said Sarah O'Connell, a lead author of the study. Thirty percent of cancers (17/56) were better seen on 2-D mammography but none were only seen on 2-D mammography. The remaining were rated by the breast imaging specialists as being equally visible on both 2-D and 3- imaging, she said.

"The majority of cancers seen better or only on tomosynthesis were predominantly infiltrating ductal carcinoma, which typically presents as a mass, focal asymmetry or architectural distortion," said O'Connell.

The majority of cancers seen better or only on 2-D mammography were ductal carcinoma in situ (DCIS) which presents as calcifications, she said. "This was not surprising because tomosynthesis gives us the ability to scroll through the breast tissue in 1 mm sections, which provides us with more detail, but also may separate a cluster of calcifications, making them more difficult to identify," said O'Connell. O'Connell noted that work is being done to optimize visualization of calcifications on tomosynthesis.

The benefits of tomosynthesis are especially relevant to women at increased risk of breast cancer who have increased anxiety about breast screening and have the potential for biologically aggressive cancers, said O'Connell.

The study is part of the electronic exhibit program at the ARRS Annual Meeting in Washington, D.C.


Related Content

News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
News | Women's Health

April 16, 2026 – GE HealthCare has expanded its collaboration with DeepHealth, Inc., a wholly-owned subsidiary of RadNet ...

Time April 20, 2026
arrow
News | Breast Imaging

April 15, 2026 — QT Imaging Holdings, Inc. has launched its QTI Imaging-Olea Viewer, developed in collaboration with ...

Time April 15, 2026
arrow
News | Breast Imaging

April 1, 2026 — QT Imaging Holdings has released its latest image reconstruction software update, version 4.5.0. This ...

Time April 02, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
News | Breast Imaging

March 30, 2026 — Each year, the Alumni Association at the University of Missouri-Kansas City, recognizes the ...

Time March 31, 2026
arrow
News | MRI Breast | Breast cancer, dense breast, MRI

March 2, 2026 — A collaborative modeling study found that adding biennial breast magnetic resonance imaging (MRI) to ...

Time March 20, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
Subscribe Now